Navigation Links
UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets
Date:12/3/2007

>The adverse events that result from Keppra(R) injection use for myoclonic seizures in juvenile myoclonic epilepsy and partial onset seizures in adults include all of those associated with Keppra(R) tablets and oral solution.

U.S. Prescribing information is available at http://www.keppra.com or by calling 1-866-822-0068.

About UCB

UCB, Brussels, Belgium (http://www.ucb-group.com) is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialisation of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology. UCB focuses on securing a leading position in severe disease categories. Employing more than 10,000 people in over 40 countries, UCB achieved revenue of 3.5 billion euro in 2006 on a pro forma basis. UCB S.A. is listed on the Euronext Brussels Exchange and through its affiliate, owns approx. 89% of the shares of SCHWARZ PHARMA AG. SCHWARZ PHARMA AG (Monheim, Germany) is a member of the UCB Group.

Forward looking statement

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.


'/>"/>
SOURCE UCB, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/6/2009)...e/ -- The Michael J. Fox Foundation awarded a tota...teams for pre-clinical research on potential new t...ing was awarded under the Foundation,s Therapeuti...unched in 2006, supports and bolsters industry-foc...t of MJFF,s focus on ,de-risking, preclinical PD...
(Date:1/6/2009)...re/ -- Pacira Pharmaceuticals, Inc., an,acute car...y that enrollment,has been completed in two pivot... and efficacy of a single intraoperative administr...ged postoperative analgesia. , Results from...,arthroplasty (TKA) are expected to provide the p...
(Date:1/5/2009)...FirstCall/ -- Micromet, Inc.,(Nasdaq: MITI ), a...ietary,antibodies for the treatment of cancer, in...utlook on key events anticipated for the year 2009... on its research and development,programs at the ...: Update on several preclinical BiTE antibodies at...
(Date:12/30/2008)...wire/ -- The Coalition for 21st Century Medicine s...ntech, Inc. on December 5, 2008, seeking to restri... tests to physicians and patients. The request th... patient care and rests on flawed scientific and l...o encourage the research, development, and commerc...
Breaking Medicine Technology:Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinson's Disease Research 2Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment 2Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment 3Micromet Key Events for 2009 2Micromet Key Events for 2009 3Micromet Key Events for 2009 4Micromet Key Events for 2009 5Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 2Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 3Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 4Quark Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference 30883 1Quark Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference 30883 2EMS Magazine Announces Top Innovation Awards for 2008 30879 1EMS Magazine Announces Top Innovation Awards for 2008 30879 2Pressure BioSciences Inc Announces Restructuring Significant Cost Reduction Initiatives and Sharpened Focus 30876 1Pressure BioSciences Inc Announces Restructuring Significant Cost Reduction Initiatives and Sharpened Focus 30876 2Pressure BioSciences Inc Announces Restructuring Significant Cost Reduction Initiatives and Sharpened Focus 30876 3Pressure BioSciences Inc Announces Restructuring Significant Cost Reduction Initiatives and Sharpened Focus 30876 4Pressure BioSciences Inc Announces Restructuring Significant Cost Reduction Initiatives and Sharpened Focus 30876 5Pressure BioSciences Inc Announces Restructuring Significant Cost Reduction Initiatives and Sharpened Focus 30876 6Pressure BioSciences Inc Announces Restructuring Significant Cost Reduction Initiatives and Sharpened Focus 30876 7IDO2 an active enzyme to target in pancreatic cancer 30873 1IDO2 an active enzyme to target in pancreatic cancer 30873 2
... ,Animal Study Confirms Caprospinol,s (SP-233) Abi...ells to Recover Memory Function , In Vivo ,Proof o...en Removing Beta Amyloid Plaque and Memory Recover...amaritan,Pharmaceuticals Inc. (AMEX:LIV), a develo... has confirmed Caprospinol,s (SP-233),efficacy in ...
...ENVER--(BUSINESS WIRE)--Jul 10, 2007 - Corgenix Me... clinical collaborators,reported new clinical data...erum levels of the Company,s patented AtherOx(TM),...as presented at,the XXIst Congress of the Internat...in Geneva, Switzerland., Data released this week s...
Other Medicine Technology:Samaritan's Alzheimer's Drug Caprospinol Suggests Brain May be Able,to Heal From Alzheimer's Disease 2Samaritan's Alzheimer's Drug Caprospinol Suggests Brain May be Able,to Heal From Alzheimer's Disease 3Corgenix Reports New Clinical Data Correlating AtherOx Technology,With Vascular Disease 2Corgenix Reports New Clinical Data Correlating AtherOx Technology,With Vascular Disease 3Corgenix Reports New Clinical Data Correlating AtherOx Technology,With Vascular Disease 4
(Date:1/8/2009)...ore effectively than Zocor , , THURSDAY,... review, U.S. health officials said Thursday that ...ial cholesterol-lowering drug Vytorin. , The U....significant difference in carotid artery thickness...ng the drug Zocor. , But, the agency reported, ...
(Date:1/8/2009)...tCall/ -- Allscripts-Misys Healthcare,Solutions, ...c. (Allscripts or,the Company), today announced i... ended November 30, 2008. , (Logo: http://...GO-b ) , The Company,s results for the thre...results from legacy Allscripts for the period of O...
(Date:1/8/2009)...swire/ -- The Pew Charitable Trusts announced toda...ical and food safety programs, in its Health &...merly deputy staff director and general counsel of...rks, brings nearly 25 years of experience in envir... , "We are excited to be joined by such an experi...
(Date:1/8/2009)...hristine Siu and Jason Brown, Ph.D. Promoted to Vi... STAMFORD, Conn., Jan. 8 Thomas, M...tal firm that invests in life science and medical ...n of three members of its investment team. Kathy ...u and Jason Brown have been promoted to Vice Presi...
Breaking Medicine News(10 mins):Health News:FDA Backs Cholesterol Drug Vytorin 2Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 2Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 3Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 4Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 5Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 6Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 7Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 8Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 9Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 10Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 11Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 12Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 13Health News:Veteran Environmental Health Expert Erik D. Olson to Join Pew 2Health News:Thomas, McNerney & Partners Promotes Three Members of Its Investment Team 2
... the most common and deadly cancer worldwide. Abou...this year out of which // 85% will die before 2010...tries, but it is fastly increasing in low and midd...lung cancer occurrence is smoking. Globally smokin...
...by the Temple University School of Medicine report...c floor disorders often do not report their discom... that eventually when they do report to their medi...ften complicated and of urogynecological nature. P...
...tories (RL) has received its first tentative appro... ) to manufacture // and market lamivudine tablets... retroviral agents (ARVs) to treat patients with H...fter a number of quality checks and inspections by...
...e identified an enzyme’s new role in aiding joint ...enzyme called cathepsin G can regulate the ability...l start the process of inflammatory conditions tha...athepsin G attracts accumulation of immune cells t...
Other Medicine News:Health News:Aggressive Tobacco taxation policy can reduce cigarette smoking, 2
...ct Complete® is a scientifically advanced nutr...ion for macular and full body health. MacularProte...nd other advanced research. It features a comprehe...d foundation of antioxidants, such as 10 mg of Flo...
Oculair (re-formulated Syntrx Complete) is a potent full-spectrum multiple vitamin/mineral/antioxidant dietary supplement that supports the normal aging process. It is designed to reflect the most re
Ocuvite® vitamin and mineral supplements contain 2 mg of Lutein 8 times more than the leading multivitamins. Ocuvite also contains vitamin antioxidants A, C and E, as well as the minerals zinc,
Most people take their eyes for granted. Like the rest of your body, your eyes need proper nutrition and care to help maintain eye health and vision as you age. In fact, research indicates proper nut
Medicine Products: